PMID- 23510293
OWN - NLM
STAT- MEDLINE
DCOM- 20140331
LR  - 20130619
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 12
IP  - 4
DP  - 2013 Jul
TI  - Safety and treatment patterns of angiogenesis inhibitors in patients with 
      advanced renal cell carcinoma in Spain.
PG  - 455-63
LID - 10.1517/14740338.2013.781581 [doi]
AB  - OBJECTIVE: To examine real-world safety and treatment patterns of angiogenesis 
      inhibitors for advanced renal cell carcinoma (aRCC) using observational data from 
      two Spanish hospitals. METHODS: A retrospective medical record review was 
      performed for 93 patients with a histological diagnosis of aRCC who received 
      sunitinib, sorafenib, bevacizumab or temsirolimus as first-line angiogenesis 
      inhibitor therapy, between January 2005 and September 2010 at two Spanish 
      hospitals. Data were collected on adverse events (AEs), dosing to calculate 
      relative dose intensity (RDI), treatment modifications and reasons for 
      modifications. RESULTS: Sixty patients received sunitinib, 23 received sorafenib, 
      6 received bevacizumab, 1 received temsirolimus and 3 received a 
      bevacizumab-temsirolimus combination. 91.7 and 100.0% of patients receiving 
      sunitinib and sorafenib, respectively, experienced >/= 1 AE; 40.0% and 43.5% had >/= 
      1 grade 3/4 AE. Mean RDI for sunitinib and sorafenib were 0.866 (standard 
      deviation (std) = 0.903) and 0.798 (std = 2.154), respectively. Among patients 
      receiving sunitinib, 15.0% discontinued treatment, 43.3% had an interruption and 
      33.3% had a reduction due to AEs. For sorafenib, these rates were 4.3, 56.5 and 
      34.8%, respectively. CONCLUSIONS: High rates of AEs were observed which resulted 
      in high rates of treatment interruptions and dose reductions. These results 
      suggest the need for additional treatment options for aRCC with improved 
      tolerability.
FAU - Castellano, Daniel
AU  - Castellano D
AD  - Hospital Universitario 12 de Octubre, Madrid, Spain.
FAU - Duh, Mei Sheng
AU  - Duh MS
FAU - Korves, Caroline
AU  - Korves C
FAU - Suthoff, Ellison Dial
AU  - Suthoff ED
FAU - Neary, Maureen
AU  - Neary M
FAU - Hernandez Pastor, Luis Javier
AU  - Hernandez Pastor LJ
FAU - Bellmunt, Joaquim
AU  - Bellmunt J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130320
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Angiogenesis Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/adverse effects/*therapeutic use
MH  - Carcinoma, Renal Cell/*blood supply/*drug therapy
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*blood supply/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Spain
EDAT- 2013/03/21 06:00
MHDA- 2014/04/01 06:00
CRDT- 2013/03/21 06:00
PHST- 2013/03/21 06:00 [entrez]
PHST- 2013/03/21 06:00 [pubmed]
PHST- 2014/04/01 06:00 [medline]
AID - 10.1517/14740338.2013.781581 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2013 Jul;12(4):455-63. doi: 10.1517/14740338.2013.781581. 
      Epub 2013 Mar 20.